Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev
https://www.zacks.com/stock/news/2200049/pfizer-pfe-stock-rises-on-fda-nod-for-expanded-use-of-padcev?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200049
Dec 19, 2023 - The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
0
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
https://www.zacks.com/stock/news/2200047/merck-mrk-gets-eu-nod-for-expanded-use-in-gastric-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200047
Dec 19, 2023 - Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
0
Alexandria (ARE) Inks Leases at its Campuses Amid Solid Demand
https://www.zacks.com/stock/news/2200025/alexandria-are-inks-leases-at-its-campuses-amid-solid-demand?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2200025
Dec 19, 2023 - Amid the booming demand for life-science assets, Alexandria (ARE) inks leases with Novo Nordisk and CARGO at its mega campuses in Greater Boston and San Carlos in the San Francisco Bay Area.
0
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
https://www.fool.com/investing/2023/12/18/these-are-the-3-hottest-biopharma-trends-of-2024/?source=iedfolrf0000001
Dec 18, 2023 - 2024 is going to be a sizzler in the biopharma sector.
0
5 Big Drug Stocks That May Continue to Outperform in 2024
https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316
Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
0
5 Non-U.S. Stocks to Buy as Wall Street Fires on All Cylinders
https://www.zacks.com/stock/news/2199250/5-non-u-s-stocks-to-buy-as-wall-street-fires-on-all-cylinders?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199250
Dec 18, 2023 - We have selected five high-flying non-U.S. companies that have strong potential for 2024. These are: NVO, NTES, TM, PDD, STLA.
0
Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2198664/has-arvinas-arvn-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2198664
Dec 15, 2023 - Here is how Arvinas, Inc. (ARVN) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
0
Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?
https://www.zacks.com/stock/news/2197201/is-it-a-good-idea-to-buy-journey-medical-derm-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2197201
Dec 13, 2023 - Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.
0
LLY Down as Patients Regain Weight After Stopping Zepbound
https://www.zacks.com/stock/news/2196988/lly-down-as-patients-regain-weight-after-stopping-zepbound?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196988
Dec 12, 2023 - Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.
0
Sanofi (SNY) Terminates Pompe Disease Deal as FTC Objects
https://www.zacks.com/stock/news/2196713/sanofi-sny-terminates-pompe-disease-deal-as-ftc-objects?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196713
Dec 12, 2023 - Sanofi (SNY) decides to end the licensing deal with Maze Therapeutics for MZE001, a phase II ready oral tablet for Pompe disease, due to the FTC's decision to block the deal.
0